Kestra Reports Positive Real-World Study Results For ASSURE Wearable Defibrillator
Kestra Medical Technologies (KMTS) reported positive results from its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study included 21,612 patients and showed 100% shock conversion success. KMTS stock closed at $28.64, up 0.07%, with no after-hours movement.
How this was made

The 30-second read
Why it matters
The positive safety and efficacy outcomes could enhance the company's market positioning and support future sales growth.
Market read
First disclosure of pivotal post‑approval study data for a listed med‑tech firm, likely to influence investor sentiment.
What to watch
Potential regulatory scrutiny on the new algorithm's claims and insurance coverage decisions.
Background
Kestra Medical Technologies (KMTS) is a U.S. listed developer of wearable cardioverter defibrillators. The ACE‑PAS study was FDA‑required and spanned 2021‑2025.
Ticker impact
Kestra Medical Technologies disclosed positive post‑approval study results for its ASSURE wearable defibrillator, meeting safety and effectiveness goals.
likely upward pressure as investors price in improved safety profile and potential market adoption.
First‑time disclosure of robust clinical data for a FDA‑required study; market typically reacts positively to such efficacy and safety improvements.
Market effects
May boost confidence in the wearable cardiac device sector and could spur competitor activity.
U.S. market focus as the study covered patients across 35 states.
Limited to companies with similar cardiac monitoring technologies.
Counterpoint
If reimbursement or adoption hurdles persist, the data may not translate into revenue growth.
Key entities
- companyKestra Medical Technologies
Developer of the ASSURE wearable cardioverter defibrillator.


